Publication Author: Armstrong PW
Filter by Author:
Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.
Westerhout CM, Alemayehu W, Cohen-Solal A, Lam CSP, Ezekowitz JA, Corda S, McMullan CJ, O'Connor CM, Armstrong PW; VICTORIA Study Group.
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW; VICTORIA and VICTOR Study Groups.
Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.
O'Connor CM, Rathwell S, Mehrotra DV, Corda S, McMullan CJ, Lam CSP, Ezekowitz JA, Piekse B, Hernandez AF, Anstrom KJ, Mentz RJ, deFilippi CR, Voors A, Ponikowski P, Butler J, Westerhout CM, Armstrong PW; VICTORIA Study Group.
Geographic Variation and Human Development Index in Heart Failure With Reduced Ejection Fraction: Insights From VICTORIA.
Cohen-Solal A, Alemayehu W, Lam CSP, Tsutsui H, Zhang J, Godoy-Palomino A, Tziakas DN, Corda S, McMullan CJ, Ezekowitz JA, Hernandez AF, Pieske B, O'Connor CM, Westerhout CM, Armstrong PW; VICTORIA Study Group.
Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial.
Gouda P, Alemayehu W, Voors AA, Lam CSP, Ezekowitz J, Pieske B, Butler J, Westerhout CM, Yogasundaram H, Sandhu RK, Armstrong PW; on behalf of the VICTORIA Study Group.
Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2.
Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristić AD, Averkov OV, Lambert Y, Temple T, Ly E, Bogaerts K, Sinnaeve P, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators.
Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2.
Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristic AD, Averkov OV, Lambert Y, Kerr Saraiva JF, Sepulveda P, Rosell-Ortiz F, French JK, Musić LB, Temple T, Ly E, Bogaerts K, Sinnaeve PR, Danays T, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators.
Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.
Kittipibul V, Mentz RJ, Young R, Butler J, Ezekowitz JA, Lam CSP, Ponikowski P, Voors A, Corda S, McMullan C, O'Connor CM, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up.
Sinnaeve PR, Welsh RC, Arias Mendoza A, Ristić AD, Averkov OV, Lambert Y, Kerr Saraiva JF, Sepulveda P, Rosell-Ortiz F, French JK, Musić LB, Vandenberghe K, Bogaerts K, Danays T, Bainey KR, Armstrong PW, Van de Werf F; STREAM-2 Investigators.
Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
deFilippi CR, Shah P, Shah SJ, Alemayehu W, Lam CSP, Butler J, Roessig L, O'Connor CM, Westerhout CM, Armstrong PW; VITALITY-HFpEF Study Group.
Comparing Analytical Methods for Composite Endpoints in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) Trial.
Westerhout CM, Rathwell S, Anstrom KJ, Hernandez AF, Ponikowski P, Ezekowitz JA, Voors AA, Felker GM, Bakal JA, Blaustein RO, Nkulikiyinka R, O'Connor CM, Armstrong PW; VICTORIA Study Group.
Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial
Tromp J, Lam CSP, Alemayehu W, de Filippi CR, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, Roessig L, O'Connor CM, Shah P, Westerhout CM, Voors AA, Pieske B, Armstrong PW; VICTORIA Study Group.
Global Collaborative Cardiovascular Research: The Collective Wisdom of Countries.
Armstrong PW.
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.
Khan MS, Butler J, Young R, Lewis BS, Escobedo J, Refsgaard J, Reyes E, Roessig L, Blaustein RO, Lam CSP, Voors AA, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
Ezekowitz J, Alemayehu W, Edelmann F, Ponikowski P, Lam CSP, O'Connor CM, Butler J, Corda S, McMullan CJ, Westerhout CM, Voors AA, Mentz RJ, Armstrong PW; VICTORIA Study Group.
Response by Van de Werf et al to Letter Regarding Article, “STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial”.
Van de Werf F, Sinnaeve P, Welsh RC, Armstrong PW.
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
Mentz RJ, Stebbins A, Butler J, Chiang CE, Ezekowitz JA, Hernandez AF, Hilkert R, Lam CSP, McDonald K, O'Connor CM, Pieske B, Ponikowski P, Roessig L, Sweitzer NK, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY-HFpEF trial.
Butler J, Khan MS, Gasior T, Erickson TR, Vlajnic V, Kramer F, Blaustein RO, Goldsbury D, Roessig L, Lam CSP, Anstrom KJ, Armstrong PW; VITALITY Study Group.
Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
Chew DS, Li Y, Bigelow R, Cowper PA, Anstrom KJ, Daniels MR, Davidson-Ray L, Hernandez AF, O'Connor CM, Armstrong PW, Mark DB, VICTORIA Study Group.
Relationship Between Baseline Electrocardiographic Measurements and Outcomes in Patients with High-Risk Heart Failure: Insights from the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
Yogasundaram H, Zheng Y, Ly E, Ezekowitz JA, Ponikowski P, Lam CSP, O'Connor C, Blaustein RO, Roessig L, Temple T, Westerhout CM, Armstrong PW, Sandhu RK, VICTORIA Study Group.
